We use cookies on our website, which are text files containing small amounts of information that are downloaded to your computer or mobile device. To find out more about the cookies we use please click here.

Some of these cookies are strictly necessary for operation of this site. Other, non-essential cookies are used for measuring website performance (which is all aggregated and anonymised) and may share this information with Google. To consent to non-essential cookies, click "Accept all non-essential cookies".

PolyTherics appoints new head of business development

21 August 2012

PRESS RELEASE

London, UK, 20 August 2012 ? PolyTherics Limited (“PolyTherics”), a provider of solutions to enable the development of better biopharmaceuticals, is very pleased to announce the appointment of Dr Georg Buchner as Vice President of Business Development. Georg will work with Jenny Filbey, PolyTherics’ business development representative in the USA and CEO John Burt, to further build on PolyTherics’ commercial success and to expand the Company’s partnering programme.

Georg joins PolyTherics from Silence Therapeutics where he held a similar position. His previous roles include Vice President of Corporate and Business Development at Novacta Biosystems Limited and Director of Business Development at Haptogen Limited, where he led the sale of the company to Wyeth Research. Georg is fluent in Italian and German, he has an MBA from the University of Cambridge and a PhD in Molecular Biology from King’s College London.

Ends

About PolyTherics

PolyTherics is a private UK biotech company that provides technology solutions to enable the development of better biopharmaceuticals. PolyTherics has developed proprietary technologies for the site-specific conjugation of polymers, such as poly(ethylene glycol) (PEG), to any therapeutic peptide or protein, including antibodies, antibody fragments and protein scaffolds. Its proprietary linker chemistry and novel reagents can be used to produce antibody drug conjugates (ADCs), bispecific proteins, and more stable proteins and peptides with longer half?lives. Products developed using PolyTherics’ technologies have significant product quality and production advantages, including better pharmacokinetic and pharmacodynamic profiles, increased product homogeneity, consistency of manufacture and more cost?effective process economics.

PolyTherics has licence agreements with Celtic Pharma and Nuron Biotech and expects products developed using its technologies to be in clinical development in the next 12?18 months. In January 2012, PolyTherics acquired Warwick Effect Polymers and extending the company’s offering to include low viscosity polymers, as an alternative to PEG, and glycopolymers for targeted drug delivery.

PolyTherics has raised over £7.5 million of private capital and is backed by a number of institutional investors, including Imperial Innovations (LON:IVO), Proven Health VCT plc, The Capital Fund, Advantage Enterprise and Innovation Fund, Mercia Funds 1 & 2, Oxford Technology VCT 3 plc and Oxford Technology 4 VCT plc, and a number of high net worth individuals with funds managed by Longbow Capital LLP.

For more information, please visit: www.polytherics.com.

For more information contact:
John Burt
Chief Executive Officer
PolyTherics Ltd
Tel: +44 (0) 207 691 3580
Email: info@polytherics.com

© Mercia Technologies 2019

Terms and conditions Privacy policy

Designed and built by Onespacemedia